Certara, Inc. (CERT)
Health Care · Drug development software and consulting / computational pharmacology · NASDAQ
Certara uses AI-enhanced biosimulation and mathematical modeling to help pharmaceutical companies reduce drug development time and cost while increasing regulatory approval odds.
What Certara, Inc. does
Certara is a global leader in biosimulation science, technology, and consulting services for Model-Informed Drug Development (MIDD), which uses mathematical models derived from preclinical, clinical, and evidence data to optimize decision-making in pharmaceutical research, development, and commercialization. The company provides proprietary biosimulation platforms, curated datasets, regulatory consulting, and AI-enhanced software solutions designed to reduce drug development costs, accelerate timelines, and increase the probability of regulatory approval. Certara's customers have received over 90% of all novel FDA drug approvals from 2014-2025, and the company serves more than 2,600 life sciences companies and academic institutions across therapeutic areas ranging from cancer to rare diseases.
Themes: ["drug development productivity / R&D optimization","AI-enhanced scientific computing","regulatory science / compliance automation","computational pharmacology / biosimulation","clinical trial design and optimization","data analytics for life sciences"]
Fundamentals
- Price$6.79 as of 2026-07-09 close
- Market cap$1.1B as of 2026-07-10
- 1-year return-42.6% as of 2026-07-09 close
- Net margin-3.6% as of 2026-07-10
- Gross margin+61.6% as of 2026-07-10
- ROE-1.4% as of 2026-07-10
- Debt / equity0.29 as of 2026-07-10
- Revenue growth (YoY)+6.4% as of 2026-07-10
- Revenue CAGR (3y)+7.7% SEC XBRL
- Beta1.42 as of 2026-07-10
Key risks (from latest filing)
["Dependence on pharmaceutical and biotech industry R&D spending, which is subject to economic cycles, regulatory changes, and strategic shifts in drug development strategy","Regulatory risk: AI and ML technologies embedded in models and documents must meet FDA transparency, reproducibility, and explainability standards, and any regulatory clarifications could impact product viability or require costly redesign","Competition from other MIDD service providers, in-house modeling capabilities developed by large pharma, and potential disruption from alternative drug development methodologies or emerging competitors with AI-native platforms"]
Competitors & peers
- Simulations Plus (SLP)
- Charles River Laboratories (CRL)
- Parexel (now part of EAE)
- Covance (part of LabCorp Drug Development)
- IQVIA (IQVS)
- Exscientia
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.